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Mechanical circulatory support is the most rapidly evolving strategy in heart
failure management. The growing number of patients who need better results
than medical therapy can offer, the limited pool of donors for cardiac
transplantation, and several technological breakthroughs have all made the
option of implanting a left ventricular assist device (LVAD) as destination therapy
more important.
In this review, we outline the indications and decision making process of
considering a patient for a destination therapy LVAD, as well as outcomes,
complications, and issues related to management of patients on currently
approved devices. The future direction of the field will be determined by progress
in technology and by further improvement in size, durability, pump dynamics, and
most importantly, by solving the problem of supplying energy to the pump without
a percutaneous driveline.
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End Destination of Heart Failure Is LVAD
The population of patients with heart failure (HF) is growing at a rate approaching
that of an epidemic. This means that although only a small fraction of patients
with heart failure progress to the end-stages of the disease, there are probably
between 100,000 and 250,000 patients in the United States who have exhausted
traditional methods of treatment, including all evidence-based medications and
pacemaker-based therapies (1).
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Meanwhile, the number of heart transplants in the United States has remained at
about 2,500 per year for several decades (2). Unless we learn how to make
better artificial hearts, or learn how to patch failing ventricles using stem cells, the
vast majority of advanced HF patients will have to be considered as potential
candidates for mechanical circulatory support. At first, LVADs were thought of as
a temporary intermediate step that can bridge patients to heart transplantation.
However, LVADs have now been used as destination therapy (DT) for more than
a decade and are quickly replacing transplants as the standard therapy.
This transition was made possible by technological breakthroughs including:
(a) conversion from external to internal placement of the devices; (b) conversion
from pneumatic to electrical power; and (c) transition from pulsatile to
continuous-flow devices. The new continuous-flow LVADs that are currently used
for DT are much smaller in size and weight and quieter in operation than the first
pulsatile models. These characteristics improve patient satisfaction and allow the
technology to support a greater variety of patients.
According to the sixth Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) annual report, more than a thousand LVADs were
implanted for DT indication in 2013(3). This represents a doubling in volume
since 2010 (Figure 1). This review builds on this clinical progress and discusses
the most important aspects of LVADs as DT.

Fig 1. Primary adult implants for destination therapy in the INTERMACS
registry by year of implant (Kirklin et al. (3), with permission).
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Brief History
In 2001, the REMATCH (Randomized Evaluation of Mechanical Assistance for
the Treatment of Congestive Heart Failure) trial demonstrated for the first time
that mechanical circulatory support as DT for advanced HF is superior to optimal
medical management (4). This trial was performed using a pulsatile HeartMate I
(HMI) (Thoratec Corporation, Pleasanton, California) device. This was later
approved by the Food and Drug Administration (FDA) for DT and subsequently
covered by Medicare in 2003.
Later, a continuous flow HeartMate II (HMII) (Thoratec) was proven to provide
better survival, quality of life, and fewer adverse events, under conditions that
included use as a DT (5, 6). Since the rotor is the pump’s only moving part, the
HeartMate II device is very durable with an estimated working life of 5 to 10
years. The pumps also have good hemocompatibility (that is, they do not cause
adverse reactions with flowing blood) and can drive adequate cardiac output
without inducing turbulence, stasis, or clinically significant hemolysis.
The FDA approved the HeartMate II LVAD for DT in January 2010. Currently,
over 98% of all LVADs implanted in the United States are continuous flow
devices (7), and the HMII has proven to be the “work horse” of LVAD centers
across the United States. At present, it is essentially the only realistic option for
large-scale implementation of LVAD DT. Heartware (Heartware, Framingham,
MA), another durable pump with good outcome data, is not yet approved for DT.

Indications
According to the most recent guidelines of the American College of Cardiology
Foundation/American Heart Association (8), VADs are indicated for patients who
have advanced systolic HF with a left ventricular ejection fraction (LVEF) less
than 25% and who are in New York Heart Association (NYHA) class III-IV
functional status. Patients must also have received guideline-directed medical
therapy including (when indicated) cardiac resynchronization therapy and have a
high predicted 1- to 2-year mortality (e.g., as suggested by markedly reduced
peak oxygen consumption or clinical prognostic scores) or be dependent on
continuous parenteral inotropic support.
The dependence on continuous intravenous inotropes can be shown for patients
with low cardiac output by demonstrating that cardiac index improves by at least
20% after initiation of inotropes (9). Alternatively, patients exhibiting pulmonary
congestion should show a ≥20% drop in pulmonary capillary wedge pressure
after inotropes (9). Patients should also fail weaning attempts implemented by an
experienced HF team.
In essence, LVAD as DT should be considered for patients who have advanced
systolic HF and who are (a) otherwise functional, (b) ineligible for cardiac
transplantation, and (c) have low-output syndrome and/or severe congestion.
This means that all patients referred for mechanical circulatory support should
already have had their transplant candidacy assessed (10). Of course, these
The VAD Journal: http://dx.doi.org/10.13023/VAD.2014.02
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plans also assume that any potentially reversible causes of systolic HF, such as
severe aortic stenosis, persistent tachyarrhythmias, ongoing ischemia, etc. have
been corrected.

Candidate Selection: LVAD, Transplant, or Hospice?
The steps for choosing treatments for patients who have advanced HF include:
•

Evaluation for reversible causes of cardiomyopathy/HF.

•

Evaluation for heart transplant eligibility.

•

In patients who are ineligible for heart transplant, evaluation for
mechanical circulatory support (Figure 1).

Many conditions that prevent a patient from being candidate for heart
transplantation do not impact the option of LVAD DT.
•

Age. Age remains the most common reason that patients are
ruled ineligible for transplant. Many programs consider patients
aged 70 and over too old to transplant. Meanwhile, patients who
are at least 70 years of age when they receive an LVAD typically
perform well with one month, one year, -and two-year survival
rates, as well as length of stay, not markedly different from data
obtained from younger patients (11-13). Thus, age alone should
not be viewed as a contraindication for LVAD.

•

Frailty. One area that is becoming an increasingly important part
of a DT evaluation is the assessment of frailty. Frailty is a
biological syndrome that reflects a state of decreased physiologic
reserve, and can be diagnosed if three or more of the following
criteria are present: unintentional weight loss (10 pounds in the
past year), self-reported exhaustion, weakness (typically
measured as grip strength), slow gait, and low physical activity.
Post-operative complications are adversely affected by frailty (14)
and handgrip has been shown to be a particularly effective
predictor of survival (15).

•

Obesity. Traditionally, transplantation centers establish an
arbitrary threshold for body mass index (BMI) which they use as a
criteria for patient selection. This contrasts with data from LVAD
procedures (16) which show that extremes of body mass index
are not associated with poor survival in either univariate analysis,
or in adjusted models (extremely obese: hazard ratio (HR) 1.29, p
= 0.2; obese: HR 0.94, p = 0.7; underweight: HR 1.23, p = 0.4).
Extremely obese patients did however have higher rates of
device-related infection and re-hospitalization (16). Butler et
al.(17) also reported good outcomes on LVADs in patients with
high BMI, with similar rates of infectious, neurological, respiratory,
and bleeding complications as their leaner counterparts, but with
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higher re-operation rates and more renal complications. Patients
with lowest BMI (<22.9) had the worst prognosis (Table 1) (17).
•

Pulmonary hypertension. Patients who have severe fixed
pulmonary hypertension (defined as pulmonary arterial systolic
pressure greater than 60 mm Hg, transpulmonary gradient greater
than 15 mm Hg, or pulmonary vascular resistance greater than 6
Wood units, while unresponsive to treatment with pulmonary
vasodilators) are very high risk candidates for cardiac
transplantation because of the high likelihood of post-operative
right ventricular failure. These patients can however be treated
with LVADs which may also reverse the pulmonary hypertension
by unloading the left ventricle (18, 19).

•

Recent malignancy. By convention, history of malignancy within
5 years is a contraindication for heart transplant, with rare
exceptions. However, if the overall prognosis is good from an
oncologic standpoint, there is no reason not to consider the
patient for LVAD DT.

•

Human immunodeficiency virus. While the fear of opportunistic
infections typically precludes these patients from heart transplant,
they can benefit from LVAD as DT (20).

•

Diabetes. Caution is needed with this condition as outcomes for
patients with LVADs and diabetes are typically as not as good as
those for non-diabetics (Odds ratio (OR) 1.76, 95%CI 1.05-2.94)
(21). Still, patients without severe end-organ damage due to
diabetes, which would be a contraindication to transplant, can
benefit from LVAD. Moreover, LVAD implantation with subsequent
hemodynamic and metabolic optimization can improve the course
of diabetes mellitus (22-26).

Congenital heart disease in adults produces more complex physiology than
simple ischemic or non-ischemic cardiomyopathy. Congenital abnormalities can
alter the chest anatomy as can prior surgeries performed for palliations and
surgical repairs. Adhesions, conduits, shunts, patches, and anastomoses create
multiple surgical challenges. Many centers avoid transplanting these patients
because their outcomes are frequently worse than those patients who have
“straightforward” advanced HF. Given the young age of many patients with adult
congenital heart disease, it is especially important to find options to prolong their
lives with mechanical circulatory support. The data on LVADs in adult congenital
cases are limited but promising. A series of 6 cases with systemic right ventricle,
including 2 patients with single-ventricle physiology, reports 2 deaths and long
survival on LVADs for the four remaining patients (27).
Contraindications for LVAD (as well as heart transplantation) include: systemic
illness with a life expectancy of less than two years, active malignancy with poor
prognosis, severe aortic disease, severe obstructive pulmonary disease, and
irreversible renal or hepatic dysfunction. The last condition does however require
careful consideration as in many cases the dysfunction is secondary to
The VAD Journal: http://dx.doi.org/10.13023/VAD.2014.02
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congestion/low output and may therefore be reversible on hemodynamic
unloading (28, 29). Sometimes a liver biopsy is warranted to differentiate
cirrhosis from potentially reversible fibrosis. If the team decides that the
risk/benefit ratio for LVAD is unfavorable, a palliative care consult should be
obtained to decide on the appropriateness of hospice. The decision making
process is summarized in Figure 2.
Advanced HF
LVEF<25%
NYHA III-IV
Optimal medical management + CRT if indicated
•
•
•
•
•

Six minute walk <300 m
Peak VO2<14 mL/kg/min
Frequent hospital admissions
Inotrope dependency
High 1- or 2-year mortality risk by risk score

Correct the reversible
cause

Ye s

Reversible Cause
No
Heart transplant/LVAD Evaluation

Eligible for transplant

Heart Transplant
or LVAD as a bridge

Not eligible for transplant
• Too old
• High BMI
• Pulmonary hypertension
• Recent malignancy
• HIV

Eligible for LVAD

LV AD

Not Eligible for
LV AD

Hospice

Fig 2. Decision making process on advanced HF management

Evaluation for LVAD as DT
The evaluation process is typically performed by a team of specialists that
includes a HF cardiologist, a cardiothoracic surgeon, a dietitian, a pharmacist, a
social worker, and a financial consultant. In most programs, the same team
performs evaluations for heart transplant and LVAD implantation.
In order to benefit from the LVAD, the patient has to (a) survive the early postoperative period when most acute complications occur, and (b) maintain good
functional status for several years in order to maintain a good quality of life after
the implant.
To solve the first problem – getting the patient through post-operative period –
their status has to be optimized before the surgery. This includes:
•

Optimizing hemodynamics with maximal unloading (diuresis with
or without inotropic support) and treating pulmonary hypertension

The VAD Journal: http://dx.doi.org/10.13023/VAD.2014.02

Page 6 of 39

The VAD Journal: The journal of mechanical assisted circulation and heart failure
	
  
	
  
	
  
to decrease pulmonary vascular resistance and prevent postoperative failure of the right ventricle (RV).
•

Minimizing renal and hepatic insufficiency.

•

Improving nutritional status.

•

Evaluating for potential bleeding and optimizing coagulation
status.

•

Treating infections
prophylaxis.

and

providing

antibiotic

coverage

for

To prepare the patients for living on LVAD support for a long time, several steps
are usually undertaken before the decision to operate:
•

Evaluating for serious co-morbidities which may limit longevity
such as severe chronic obstructive pulmonary disease, severe
vasculopathy, including atherosclerotic changes in carotis arteries
or presence of peripheral vascuoar disease, impaired neurologid
status, or coagulopathy.

•

Evaluating psychological stability, compliance, absence of drug or
alcohol addiction, social support, and financial reserves.

Selecting the best candidates for LVAD DT involves optimizing the balance
between patients who are “too sick” and patients who are “too well”. Extensive
prognostic data is available from INTERMACS, the unique registry of LVAD
recipients in the USA which is sponsored by the National Heart, Lung, and Blood
Institute, the Centers for Medicare and Medicaid Services, FDA, and industry.
Patients who are entered into the registry are categorized into one of seven
classes at the time of LVAD implantation. The highest INTERMACS profile
(profile 1, “crash and burn”) corresponds to cardiogenic shock while profile 7
equates to stable NYHA III (30).
Unstable patients in cardiogenic shock (“crash and burn” INTERMACS profile 1)
have the worst outcomes after they receive an LVAD but also have the most to
gain if the treatment is successful (31). More stable patients in profiles 3 and 4
have much better outcomes but their gains in terms of longevity and quality of life
are moderate. Presumably technical advances will mean that each new
generation of pump will become better and smaller, and cause less discomfort to
the patient. This will make LVADs a better option for patients with milder forms of
HF. The ongoing MEDAMACS study is designed to address this idea and tests
whether ambulatory patients who are in NYHA III with episodes of
decompensation can benefit from current LVAD therapy. It’s also pertinent to
note that some programs implement risk stratification and mortality prediction
using well validated scores such as the Heart Failure Survival Score (32) and the
Seattle Heart Failure Model (33).
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Outcomes
The field of mechanical circulation has been evolving so rapidly, and
technological advances have been occurring so frequently, that the data on
outcomes have been improving continuously. The results of yesterday are no
longer valid today, and cannot be extrapolated into tomorrow. Outcomes
obtained with pulsatile pumps are not applicable to continuous flow devices, and
survival and other important outcomes have improved in each successive trial as
clinicians gain experience.
Table 1 shows data on outcomes that we collated from the literature.. Many of
the results were obtained from studies that included DT and Bridge to Transplant
(BTT) and from different types of LVAD. Outcomes from trials that studied only
BTT were not included. Most of the data in Table 1 are survival and length of stay
values.
The historic starting point for LVAD DT outcome trials is the REMATCH trial. In
this work, survival on the pulsatile HMI was 52% at one year and 29% at two
years which greatly exceeded the survival rates on optimal medical therapy (one
year, 23%; two year, 8%) (4). Since 2001, the survival of patients receiving
optimal medical management has very modestly improved but the survival of
patients receiving LVAD HT has continued to increase.
Several years later, in the HMII DT trial, patients ineligible for transplantation
were randomized into continuous flow or pulsatile flow pumps (6). Patients who
received HMII devices had better 2-year survival free from disabling stroke
and/or re-operation to repair or replace the device than patients who were
implanted with the pulsatile pump (46% versus 11%, p<0.001). Patients on HMII
also had superior actuarial survival rates at 2 years (58% vs. 24%, p=0.008) and
fewer complications.
Long term follow-up of HMII patients who were enrolled in the BTT trial showed
an overall 18-month survival of 72% (5). Interestingly, patients who were enrolled
later in the trial had better outcomes than patients who were enrolled near the
beginning (34). The later cohort had better overall survival and fewer
complications such as bleeding, device-related infections, and hemorrhagic
stroke. This trend may reflect the growing skill and experience of the LVAD
teams.
Heart transplantation is still regarded as the gold standard treatment for
advanced HF and has an average 2-year survival of approximately 80% (2).
However survival rates for LVAD DT are now approaching this level. Patients
who receive a continuous flow LVAD and who do not have risk factors associated
with high mortality (for example, history of cancer, high blood urea nitrogen,
and/or cardiogenic shock at implant) have 1 and 2 year survival rates of 88% and
80% respectively (35). The sixth INTERMACS report shows that actuarial
survival at 1 and 2 years is 80% and 70% respectively (3).
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Fig 3. Actuarial survival for continuous flow LVADs (From Kirklin et al. (3),
with permission)
Some programs create a so-called “alternative” wait list for patients who have
advanced age, diabetes, obesity, or renal dysfunction and transplant them with
sub-optimal hearts that would otherwise be discarded. These hearts typically
have left ventricular hypertrophy, mild systolic dysfunction, or some coronary
artery disease. The survival rates for patients who receive these hearts, by a
single center data, is similar to LVAD DT at one year (82.2% and 77.5%,
respectively) and better than LVAD DT at three years (73% versus 50%).
However, when patients who received pulsatile LVADs are excluded from the
analysis, the outcomes for transplant and LVAD DT are similar at three years as
well (36).
Predictably, when patients are unstable at the time of implantation, their
outcomes are not as good as those of patients who were hemodynamically
stable. An analysis of three groups of patients with different degrees of HF acuity
showed that the patients who were most stable (ambulatory HF, INTERMACS
profiles 4 to 7) had the best survival rate (96%), patients in the intermediate
group (inotrope-dependent, INTERMACS profiles 2 or 3) had a moderate survival
rate (69%), and patients in cardiogenic shock (INTERMACS profile 1) had the
worst outcomes (51% survival) (31).
Table 1 (see page 10A-10F) shows that two year survival rates for continuous
flow LVAD DT are generally in the 60~80% range. This is a substantial
achievement given that the survival rate with optimal medical therapy was only
8% when the REMATCH trial was performed 15 years ago. Overall quality of life
with LVAD DT is also good. In patients supported by predominantly HMII devices
for at least a year, the average six minute walk distance was ~400 m while they
The VAD Journal: http://dx.doi.org/10.13023/VAD.2014.02
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mean NYHA class was 1.4 +/- 0.6. These patients did however require about
three hospital admissions per year and 77% had to undergo additional operations
(37).

Myocardial Recovery
Although it is not common, myocardial recovery is a highly desirable outcome of
LVAD implementation. Replacing a failing heart with a mechanical pump
produces multiple beneficial effects. For example, LVAD implantation decreases
left ventricular dimensions, increases left ventricular ejection, and induces
regression of cardiomyocyte hypertrophy (41). Hemodynamically, LVADs
increases cardiac output, decrease pulmonary capillary wedge pressure (42) and
pulmonary vascular resistance (18, 19), and eventually improve right ventricular
structure and function. Moreover, LVADs decrease plasma epinephrine,
norepinephrine, arginine vasopressin, renin and angiotensin II (43) as well as
circulating and myocardial inflammatory mediators such as interleukin 2 and
tumor necrosis factor (44). The renal and hepatic dysfunction that is typical of
end stage HF, improves as well (45, 46). Six months of LVAD treatment
essentially normalizes liver enzymes, bilirubin, blood urea nitrogen, and serum
creatinine in patients who had previous renal and hepatic dysfunction and also
maintains values in patients who had normal pre-LVAD levels (29, 47).
Specifically, in patients with HMII, overall LVEF increased from 17% at the time
of implantation to 25% 6 months later (p < 0.01). LV mass decreased from 114
g m-2 to 95 g m-2 30 days after LVAD implantation and continued to fall
progressively over the 1-year follow-up. Interestingly, LVEF improved to >40% in
a significant proportion (19%) of patients. Most of the improvement in LVEF was
achieved within 6 months with little if any improvement after this cutoff (48).
Younger age and shorted duration of HF were the main predictors of recovery.
Importantly, the patients who recovered LVEF received the same post-VAD
cardiac medications and had the same incidence of non-ischemic cardiac
disease as the patients who did not recover LVEF (48).
Ultimate success of LVAD-associated myocardial recovery implies successful
explantation of the LVAD followed by sustained normal cardiac function. The
typical rate of explantation in patients with non-ischemic cardiomyopathy is
10~20% (49) although there are also some outlying studies that have much
higher recover rates (50, 51). Since the number of patients qualifying for LVAD
DT is expanding rapidly, a considerable number of patients could potentially be
explanted in the next few years. Recovering myocardium should be a goal in
most LVAD implants, at least in non-ischemic patients.
Dandel et al. (52) have proposed a protocol to help ensure stable cardiac
function after the explant, and to minimize the risk of having to re-implant the
LVAD if the attempt to remove mechanical support fails. They suggest turning the
LVAD to its minimum speed (6200 revolutions per minute for the HMII) and only
proceeding with the VAD explantation if LVEF recovers to ≥45%. This test
predicts cardiac stability that lasts for at least 5 years in 79% of cases. Increasing
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Table 1 Outcomes of patients on LVADs (Studies with BTT only are not included. Either mixed DT/BTT or DT only are
included.)

Setting

Patients

Indication

Device

Measure

population

1

6

month

months

1 year

2

3

Actuarial

years

years

survival

Pulsatile LVADs
Rose et al.,

REMATCH

68 patients

DT

HMI

Survival

52%

Butler et al.,

Multiple

222 patients

Mixed

Novacor

Survival

84.1%

57.5%

42.4%

2005 (17)

centers

Survival

81.3%

35%

26%

81.3%

60%

34.9%

92.1%

65%

50%

81.8%

73%

66%

29%

2001 (4)
BTT and
DT
1st quartile
BMI <22.9
2nd quartile
BMI 22.9 to
26.3
3rd quartile
BMI 26.4 to
29.4
4th quartile
BMI >29.4

10A

Butler et al.,

Multiple

2005 (21)

centers

222 patients

Mixed

Novacor

Survival

BTT and
DT
57 patients

76.6%

45.6%

30.4%

86.7%

62.4%

47.1%

with diabetes
165 patients
without
diabetes
Lietz et al.,

280

DT

HMI

37

DT

Novacor

DT

HMI and

86.1%

56%

30.9%

2007 (38)
Rogers et

The INTrEPID

al., 2007

(Investigation

(39)

of

46%

27%

NontransplantEligible
Patients Who
Are Inotrope
Dependent)
trial
Mixed pulsatile and continuous flow LVADs
Long et al.,

Utah Artificial

2008 (40)

Heart Program

23

Survival

77%

77%

HMII

10B

Daneshmand Duke

60 patients

et al., 2010

ineligible

University

(36)

DT

HMI and

Survival

93%

78%

50%

HMII

for standard
list cardiac
transplantation

Kirklin et al.,

INTERMACS

1287

DT

2012 (35)

HMI and

75%

62%

55%

24%

HMII

Randomized trial of pulsatile versus continuous flow LVADs
Slaughter et

Randomized

al., 2009 (6)

controlled trial

66

DT

HMI

Survival
Survival free

11%

from disabling
stroke and
reoperation
134

HMII

Survival
Survival

68%

58%
46%

survival free
from disabling
stroke and
reoperation
Continuous flow LVADs
Adamson et

Single center,

55

Mixed

HMII

Survival

10C

al., 2011 (11)

trials at a

BTT and

community

DT

hospital
30 patients

97%

75%

70%

96%

72%

65%

aged ≥70
25 patients
aged ≤70
Boyle et al.,

University of

2011 (31)

101 patients

Mixed

HMII or

Actuarial

Minnesota,

BTT and

VentrAssist

survival from

University of

DT

the date of

Pittsburgh and

implant to

Columbia

death,

University

transplantation,
LVAD
explantation, or
if they
remained
LVAD on
September 1,
2009
28 patients

51.1%

INTERMACS

10D

profile 1
(cardiogenic
shock)
49 patients

68.8%

INTERMACS
profiles 2 or 3
(inotropedependent
and
hospitalized)
24 patients

95.8%

INTERMACS
profiles 4 to 7
(outpatients
with low
functional
capacity)
Brewer et al.,

The HMII BTT

2012 (16)

and DT trials

896 patients

Mixed

HMII

BTT and
DT
48
underweight

73±7%,

59±
9%

10E

patients
(BMI<18.5)
596

71 ±

60±

normal weight

2%,

2%

76 ±4%

66±

patients (BMI
18.5-30)
164 obese
patients (BMI

5%

30-35)
88 extremely

79 ±5%

obese patients

68±
6%

(BMI≥35)
Park et al.,

The HMII DT

2012 (34)

trial

DT
133 patients

HMII
68±4%

58±4%

73±3%

63±3%

(early cohort)
281 patients
(mid-trial
cohort)

10F
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the LVEF threshold to ≥50% increases the predictive value of the weaning test to
92%.
Table 2. Recovery of left ventricular function as defined by successful
explantation of the device (from Guglin et al. (53))
Study, year Total
number
of
patients

Number
Number of
(%) of
nonischemrecovered ic patients
overall

Number (%) Outcomes
of
nonischemic patients
recovered

Mancini et
111
al., 1998 (54)

5 (4.5%)

51

4 (7.8%)

20% survival with
no recurrence of
HF at 15 months

Farrar et al.,
2002 (55)

22 (8.1%)

271

22 (8.1%)

86% and 77%
transplantation-free
survival at 1 year
and 5 years

Gorscan et 18
al., 2003 (56)

6 (33.3%)

13

5 (38.5%)

No HF recurrence
in 67% at 1 year

Simon et al., 154
2005 (57)

10 (6.4%)

74

8 (11%)

80% alive and free
from transplant at
1.6 ± 1.1 years

Matsumiya et 11
al., 2005 (58)

5 (45.5%)

11

5 (45.5%)

No HF recurrence
during follow-up
ranging 8 to 29
months

Dandel et al., 131
2005 (49)

32 (24%)

131

32 (24%)

68.8% had no
recurrence at three
years

Birks et al.,
2006 (51)

11 (73.3)

15 (100)

11 (73.3)

Long term survival
91%, rate of
freedom from
recurrent HF
among the
surviving patients
100% at 1 year and
88.9% at 4 years

6 (9%)

37

5 (13.5%)

No death or
transplants at 6

271

15

Maybaum et 67
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Study, year Total
number
of
patients

Number
Number of
(%) of
nonischemrecovered ic patients
overall

Number (%) Outcomes
of
nonischemic patients
recovered

al., 2007 (59)

months

Dandel et al., 188
2008 (60)

35 (18.5%) 188

35 (18.5%)

Transplant-free
survival 76.2 ±
8.1% and 70.7 ±
9.2% at 5 years
and 10 years

Birks et al.,
2011 (50)

12 (63.2)

12 (63.2)

83.3% survival
without HF
recurrence at 1 and
3 years

3

Number of patients
with ischemic/
nonischemic
cardiomyopathy
and long-term
follow-up is not
reported

19

Lamarche et 17
al., 2011 (61)

4 (23.5%)

19 (100)

Complications
1. Right ventricular failure
A downside of LVAD DT is frequent re-admissions related to complications.
These can occur soon and long after the operation. Right ventricle (RV) failure is
one of the most important problems.
Augmenting the failing LV with an LVAD improves hemodynamics immediately in
patients with isolated LV failure. The situation is more challenging for patients (for
example, most patients with ischemic cardiomyopathy) who have biventricular
failure. Since no devices are yet approved for DT for right or bi-ventricular failure,
the risk of RV failure post-LVAD needs to be assessed before every potential
implantation. We have recently published a detailed discussion of risk predictors
and risk scores that are relevant to candidate selection (62).
Increased blood flow in the postoperative period after LVAD implantation raises
the workload of the RV. The septum is also shifted to the left which increases the
RV’s end-diastolic volume and compromises its contractility. If the RV was
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already compromised before LVAD implantation, it may recover slowly, or not at
all, after the surgery (48). The most favorable scenario is a gradual reduction of
RV volume, ventricular mass, diameter of cardiomyocytes, and normalization of
myocardial collagen content and chamber stiffness (63, 64).
Specific data obtained from DT HMII patients 1 month after surgery are as
follows (65).. Central venous pressure decreased from 12.4 ± 5.9 to 8.7 ± 4.5
mm Hg (p < 0.001). Systemic pulmonary arterial pressure decreased from 52.3 ±
14.1 to 36.8 ± 11.3 mm Hg (p < 0.001). RV ejection fraction increased from 33.1
± 4.9% to 40.4 ± 6.2% (p < 0.001). In addition, RV end diastolic dimension
decreased, RV stroke work index improved, and qualitative RV function on
echocardiography improved from 57.1% moderately or severely reduced preoperatively to 38.1% after 1 month (p = 0.008).
RV failure occurs when a patient exhibits at least two weeks of inotrope
dependency, or if the patient develops late onset inotrope dependency within two
weeks of the LVAD implantation, or if they need an RVAD. This happens in 513% of patients after LVAD implantation, and results in prolonged intensive care
stay, higher mortality, greater risk of bleeding, and more renal insufficiency (66,
67).
Measurements that indicate potential postoperative RV failure include: low
fractional area change and stroke-work index estimated by echocardiologry, high
central venous pressure (even with normal or near normal pulmonary capillary
wedge pressure), elevated liver enzymes and creatinine (as signs of congestion),
and low or normal pulmonary artery systolic pressure. The Berlin group uses the
RV-to-LV end-diastolic diameter ratio of >0.72 to identify patients with high risk
for postoperative RV failure (68).
Several scores have been proposed for calculating the risk of RV failure post
LVAD. One of them emphasizes requirements for vasopressors, liver function,
and creatinine (69) while another other score highlights hemodynamic
parameters (70). Focusing specifically on RV failure after HMII, Kormos et al.
(71) identified a central venous pressure/pulmonary capillary wedge pressure
ratio of greater than 0.63, need for preoperative ventilator support, and blood
urea nitrogen level of greater than 39 mg dL-1 as independent predictors of RV
failure after LVAD. In practice, despite all of these studies, it remains challenging
to predict the post-LVAD performance of the RV for an individual patient.
Deswarte et al. (72) gave dobutamine (maximal dose 15 mcg kg-1 min-1) to
patients before they received an LVAD. The authors showed that if dobutamine
increased the tricuspid annular plane systolic excursion by at least 40% and/or
pulmonary artery systolic pressure by at least 30%, this ruled out post-LVAD RV
failure with 100% specificity and sensitivity.
Treatment strategies for post-LVAD RV failure include decreasing RV afterload
with intravenous vasodilator agents (especially phosphodiesterase-inhibitors
such as Sildenafil) and increasing contractility with inotropes such as milrinone or
dobutamine. Milrinone has been show to be the most effective inotrope for
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reducing pulmonary vascular resistance and increasing LVAD flow (73). Some
surgeons initiate inhaled nitric oxide in the operating room but this policy often
requires simultaneous use of vasopressor agents to offset the associated
vasodilation and resultant hypotension.
It has also been shown that repairing the tricuspid valve in patients with
moderate-to-severe or severe tricuspid regurgitation at the time of LVAD implant
can prevent RV failure in post-operative period (74, 75).
In general, RV failure that develops early in the postoperative phase can be
overcome using inotropes and short-term or intermediate-term devices for RV
mechanical support. RV failure that develops late, or which persists for months
after LVAD implantation, is more difficult to manage. Sometimes patients are
discharged on inotropes, or their transplant status is reconsidered, and they are
put on the waiting list.
2. Gastrointestinal bleeding
Managing complications is critical if patients receiving LVAD DT are to maintain a
good quality of life. Bleeding in general is the most common complication in
patients on LVADs, with major bleeding observed in about 20% -45% of cases
(76, 77). Patients on continuous flow support require anticoagulation and have
transfusion requirements which are double those of patients on pulsatile pumps
(77). In the HMII DT trial, as many as 81% patients required a blood transfusion,
and 30% required re-exploration for bleeding (6).
Gastrointestinal (GI) bleeding in particular is the most serious problem
associated with LVAD DT. It significantly reduces the quality of life of many
patients, leading to multiple admissions, unpleasant diagnostic tests, repeated
blood transfusions, and generally unsatisfactory solutions.
GI bleeding affects 18 to 40% of patients with LVADs (77-81). Counting only
episodes requiring transfusions of ≥ 2 units of packed red blood cells within 24
hours, Boyle et al. (82) reported GI bleeding in 9.4% of outpatients who were
supported by a HMII device. These events formed 50% of all recorded bleeding
incidents and were occurring a rate of 0.23 events/patient-year.
The proportion of patients who bleed repeatedly is 44% (78). The majority of
these individuals (60%) bleed from the same site. The distribution of bleeding
sites is as follows: upper GI tract, 89% (including 54% bleeding from gastric
erosions, 15% from gastric ulcers, and 15% from angiodysplasias), lower GI
tract,35% (equally distributed between cecal/rectal ulcers and small bowel
angiodysplasias) (78). The mean time to bleeding the LVAD implantation was
128 ±155 days.
Additional data suggest that 31% of GI tract bleeding events are caused by
arterio-venous malformations (79). Since malformations in the proximal jejunum
cannot be detected by routine upper endoscopy and are highly prevalent in
patients receiving LVAD DT, many centers now perform capsule endoscopy as
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part of the early evaluation of GI bleeding. Risk factors for GI bleeding include
advanced age, prior GI bleed, a high international normalized ratio (IRN), and low
platelets (78). Fortunately, the death rate (even in recurrent GI bleeding) remains
only 1% (78).
Aggarwal et al. (78) analyzed echocardiograms and showed that the aortic valve
opened in 17% of patients who had GI bleeds and 30% of non-bleeders. This
suggests a potential link between pulsatility and GI bleeding. However the intergroup difference was not statistically significant, potentially due to the relatively
small sample size.
Factors that may contribute to the high incidence of GI bleeds in patients who are
supported by HMII devices include:
•

Narrow pulse pressure with limited pulsatility. As in the case
of tight aortic stenosis (Heyde’s syndrome) (83), low pulse
pressure causes hypoperfusion and hypoxia of the gut, resulting in
vascular dilatation and angiodysplasia (78)

•

Acquired von Willebrand syndrome. This condition is also
associated with severe aortic stenosis (84) and is probably caused
by mechanical depletion of high-molecular-weight von Willebrand
factor multimeres. Multimeres are lost within days of the LVAD
implant (85), possibly due to the effects of shear stress on the
structure of von Willebrand factor (76, 77, 86).

•

Neoangiogenesis. Some fragments of von Willebrand factor may
be proangiogenic and actually promote angiodysplasia (76, 87).

•

Impaired platelet function. Platelet numbers, function, and
activation are reduced in patients who are supported with
continuous flow LVADs (76, 88).

Unfortunately, none of these factors fully explain why some patients develop
chronic recurrent GI bleeds and others do not. Many centers have therefore used
their clinical experience to develop protocols that they follow in the event of GI
bleeding. One of the typical protocols (78) includes:
•

holding of all anticoagulation and antiplatelets agents.

•

decreasing the VAD speed to create pulsatility

•

administering proton pump inhibitors.

•

administering octreotide (either as a continuous infusion or by
subcutaneous injection).

•

resuming anticoagulation at a lower INR goal of 1.5-2.0.

Although it seems physiologically advantageous to have some pulsatility, LVAD
speed and pulse index are not consistent predictors of GI bleeding. In one study,
reduced pulsatility index was associated with an increased risk of bleeding
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(hazard ratio, 0.60; 95% confidence interval, 0.40-0.92; P=0.02) (89), while in
another study, VAD speed and PI were not significant predictors of GI bleeding
(78).
Octreotide is a synthetic somatostatin analogue which inhibits gastric acid
secretion and reduces portal and splanchnic circulation. There is some evidence
that it is helpful. Nardone et al. (90) showed that subcutaneous injections for 6
months produced full or partial control of bleeding in 14 of 17 patients with
angiodysplasias. On the other hand, Barbara et al. (91) reported no favorable
effect. Similarly, a study showed that octreotide did not impact the amount of
packed red blood cells used, rebleeding rates, length of hospital stay, or allcause mortality (78).
There are some anecdotal reports of patients being off all anticoagulants for
months after a major bleed. However, these practices may raise the incidence of
pump thrombosis. There is also a report of successful use of danazol, a synthetic
steroid that has weak androgenic and anti-estrogenic effects (92).
3. Pump thrombosis
Pump thrombosis is a serious and potentially fatal complication of LVAD therapy.
If thrombosis is not treated with a heart transplant or LVAD replacement, the
mortality approaches 50%. In clinical trials, the rate of thrombosis was low, but
between 2011 and 2013 several high volume centers documented a sharp rise
(from 2.2% to 8.4%) of pump thrombosis in the first three months after the
implantation. The time from implant to pump thrombosis also shortened from
18.6 to 2.7 months (93). This increase was also apparent in an analysis of
INTERMACs data (94).
Preexisting LV thrombi that are dislodged during the surgery can be pulled into
the LVAD device. This problem becomes less frequent as surgeons gain
experience. A more important problem is formation of new thrombi after the
LVAD has been implanted. The heat generated by the LVAD can cause new
clots to form and grow on the inflow bearing or on the rotor itself (95).
Prothrombotic conditions can facilitate this process (96). These include:
significant infection, sub-therapeutic anticoagulation, low flow state, hereditary
thrombophilias such as protein S, protein C, or factor V Leiden deficiency, and
antiphospholipid syndrome (95).
The surgical technique also seems to influence pump thrombosis and
malposition of the inflow cannula and deformed outflow grafts have been linked
to post-LVAD clots (97). Decreasing the LVAD flow to facilitate intermittent
opening of the aortic valve increases the rate of thromboembolic events (98).
This may be because high flow rates dissipate heat from the LVAD more
effectively than low flow conditions. Clinically, it is thus important to achieve a
balance between a high flow rate (which reduces thrombosis) and a low flow rate
(which increases the incidence of bleeding).
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Pump thrombosis typically presents with evidence of hemolysis clinically manifest
as very dark cola colored urine, and a plasma free hemoglobin >30 mg dL-1,
elevated lactate dehydrogenase, decreased haptoglobin, increased pump power,
new palpable pulse, new opening of the aortic valve, worsening of mitral
regurgitation on echocardiography (99), and sometimes symptoms of HF. Data
suggest that increased lactate dehydrogenase (>600 U/mL for HMII and >400
U/mL for Heartware) is the most reliable predictor of pump thrombosis (100), and
some centers have adopted the policy of immediate hospitalization based on
elevated LDH alone. The best way to treat patients who have elevated LDH but
no clinical signs of pump thrombosis is still unclear.
Some cases may be diagnosed with CT angiography (101) but while both
cannulae can be visualized, the pump itself is not radiolucent. Recently, specially
designed ramp protocols were suggested as a way to determine the presence of
thrombi inside the LVAD device (102, 103). In addition to increasing the standard
antithrombotic and anticoagulation drugs, thrombolytics and IIB/IIIA antagonists
have been used empirically with intermittent success but multiple complications.
Frequently, the only realistic option is pump exchange. This procedure is
relatively safe for HMII devices with postoperative deaths within 30 days of 6.5%
(104) (Table 3).
Table 3. Outcomes of pump thrombosis with different therapeutic
interventions
Source

N

LVAD

Intervention

Outcome

Thenappan et
al. (105), 2013

2

HMII

Alteplase
(after heparin
and
eptifibatide
failed)

Alteplase – 100%
success
Eptifibatide 100%
failure
No complication
reported, but long
term outcome not
specified

Al-Quthami et
al. (106), 2012

2

HMII

Eptifibatide

100% success, GI
bleed in both

Tellor et al.
(107), 2013

17
patients,
total of 22
attempts

16 HMII,

Eptifibatide

3 (17.6%) –
success

1
Heartware

14 (22.4%) –
failure, including 7
(41.2% deaths)
Complications:
bleeding
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11 pts (64.7%)
including SAH in 2
Conclusion:
Risk of using
eptifibatide
outweighs the
proposed benefit of
salvaging the
existing LVAD. No
correlation between
the dose and the
outcome.
Hasin et al.
(108), 2013

8

HMII

6 Heparin+
clopidogrel

All survived acute
episode but had
recurrent
hemolysis, stroke in
1

1
Heparin+clopi
dogrel
+eptifibatide

(100% failure)

1 Heparin
+alteplase

100% success
(resolved but GI
bleed with 12 units
transfused)

100% failure

In 4 pumps which
were eventually
explanted, the clot
was present in all.
Schlendorf et
al. (109), 2014

8

Muthiah et al.

5
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(110), 2013

hemithorax
1 alteplase
and
tenecteplase
success

1 tenecteplase
died

7
episodes
in 6
patients

Heartware

100% failure

1 alteplase
died

100% failure

1 alteplase+
tirofiban

100% success but
transplant in 8 days
therefore no long
term f/u

Clopidogrel
used in 4 of 5

Aissaoui et al.
(111), 2012

100% success, with
epistaxic

5 pump
exchanges (1
after failed
tenecteplase)

No intracranial
bleeds
Pump exchange
100% successful
Tenecteplase 50%
successful

2 tenecteplase
Najjar et al.
(112), 2013

34
episodes
in 31
patients

Heartware

30 medical
therapy

4 heparin

19 alteplase
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with 5 bleeding
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urgent transplants,
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6 epitifibatide

16 pump

Alteplase 12 of 19
(63.2%) success

exchanges
3 (50%) success

12 (75%) success
4(25%) deaths

No statistical
difference in
survival at 6
months between
those
patients treated
medically
compared to
patients that
underwent device
exchange (91.7%
vs. 68.8%)
Starling et al.
(93), 2014

38

HMII

Medical
management,
no details

Pump
exchange

19

18 (50% success)

18 (95.5% success)

Ota et al.
(113), 2013

19 with
HMII
pump
thrombosi
s, out of
30 total

Pump
exchange

27 (90%) success,
3 death (10%) for
the whole cohort,
without subanalysis
by the cause

Pagani et al.
(114), 2009

4

HMII

Pump
exchange

2 (50%) success, 2
died

Stulak et al.

14 with
pump

HMII

Pump

Overall excellent
results, not
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(115), 2013

thrombosi
s, out of
57 total
episodes

Ravichandran
et al. (116),
2013

9

Kirklin et al.
(94), 2014

383 (all
pump
exchange
s due to
thrombosis)

exchange

stratified by type of
the device or the
reason for
exchange

HMII

Pump
exchange

3 (33%) success

HMII

Pump
exchange

Freedom from
pump thrombosis,
97% at 6 months,
95% at 1 year, and
92% at 2 years

The survival after
pump exchange for
thrombosis was
56% at two years
compared to 69%
(p<.0001) following
primary implant.

Although pump
exchange can be
performed with a
relatively low
hospital
mortality, survival
during the
subsequent 6
months is
adversely affected
with each pump
exchange.
Moazami et al.
(104), 2013
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s out of
72
patients
exchange
d for all
causes

The 30-day
operative 6.5% (5
of 77)
For the 66 patients
with HMII to HMII
exchange
procedures, at 1
year, mortality was
30% + transplant
5%, 65% alive on
LVAD

77
exchange
procedur
es total

The freedom from
major device failure
at 12 months was
93% ± 2%.
Badiye et al.
(117), 214

4

HMII

3(75%) success
with tamponade
due to
hemopericardium,
subdural
hematoma, and GI
bleed

Argotroban

Note that in Table 4, the data reported for pump exchange include only studies
where the exchange was performed specifically for pump thrombosis. This
excludes results from Ota et al (113), Moazami et al (104), and Stulak et al (115).
Data from Kirklin et al (94) were also excluded because the medical strategies
preceding pump exchanges were not reported. If these data had been included,
the success rate for pump exchange would have increased substantially.
Table 4. Outcomes of pump thrombosis grouped by interventions (derived
from Table 3)
Pump
exchange

Thrombolytics

IIB/IIIA
antagonists

N

53

35

33

Success

40

19

13

Success, %

75.5

54.3

39.3
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Stroke
There are two forms of stoke in LVAD patients, ischemic and hemorrhagic. The
annual ischemic stroke rate with optimal medical treatment is 5.2% (4). Boyle et
al. (82) reported ischemic and hemorrhagic stroke rates per patient-year at 4.1%
and 3.2%, respectively.
A factor that seems to influence the incidence of stoke is the level of
anticoagulation. About 40% of ischemic strokes occurred at INR < 1.5, and 33%
of hemorrhagic strokes occurred at INR > 3.0 (82). Routine aspirin therapy (81
mg daily) and maintaining INR in the 1.5 to2.5 range may balance the risks of
thrombosis and hemorrhage (82). The risk of ischemic stroke is increased if
mean arterial pressure is above 90 mmHg and if there is a history of stroke. The
odds almost double in the presence of systemic infection (118).
Table 5 summarizes the incidence of strokes in LVAD studies.
Table 5. Hemorrhagic stroke, and ischemic stroke rates in patients with
HMII implanted for DT or BTT indications (modified from Eckman et al. (76),
with permission)
Hemorrhagic CVA
per Patient-Year

Ischemic CVA per
Patient-Year

HMI/HMII (119)

0.05

0.13

HMII (5)

0.05

0.09

HMII (6)

0.07

0.06

HMII(120)

0.01

0.06

HMII (121)

0.04-0.07

0.04-0.09

Heartware (122)

0.08

0.05

HMII (82)

0.032

0.041

Infection
Drivelines that pass through the patient’s skin to the implanted device are an
“Achilles heel” of prosthetic pumps because it makes driveline infections a
permanent threat. In the HMII DT trial, the rate of LVAD-related infections was
0.90 and 0.50 events/patient-year for HMI and HMII respectively (6).
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In patients supported primarily by HMII devices for at least a year, infectious
complications led to 43% of re-admissions and occurred in the driveline (47%),
blood (37%), and LVAD pocket (20%) (37). In a prospective multicenter study of
VAD infections, where 57% of patients had HMII devices, 22% of patients
developed VAD-related infections with an incidence rate of 0.10 per 100 persondays. The driveline was the most commonly infected site, with Staphylococcus
being the most common pathogen, followed by Pseudomonas or other Gramnegative bacteria. Importantly, there was no difference between HMI and HMII,
but regardless of the device, infection increased one-year mortality (adjusted
hazard ratio=5.6; P<0.0001) (123).
In the Mayo clinic cohort, driveline infections were also the most common (47%),
followed by bloodstream infections (24% VAD-related, 22% non-VAD related).
The most common causative pathogens include gram-positive cocci (45%) and
gram-negative bacilli (27%). Only 42% of the patients were managed by
antibiotics while others had to undergo surgical procedures. A small number of
patients had to have their LVAD removed (124). Importantly for DT patients, the
odds of having a driveline infection increase by 4% for every month of support
(125).
Prevention of the infection is achieved by surgical techniques, stabilizing the
driveline to minimize motion, and meticulous attention to hygiene. Aseptic rules
should be followed and patients and their caregivers should wear sterile gloves
and a mask as they clean the exit site daily with antimicrobial soap. After
cleaning, the site should be rinsed with sterile saline and covered with a sterile
gauze.

Aortic Regurgitation
Aortic regurgitation may create problems in LVAD patients. If regurgitant flow
persists throughout systole and diastole, this can limit forward flow to the
periphery. This can compromise end-organ perfusion even when the LVAD flow
readings are abnormally high (7 to 10 L min-1) (126). While minimal symptoms
can be addressed with diuretics and afterload reduction, surgical repair or
replacement of the aortic valve may be needed in more serious cases (126).
Because aortic regurgitation tends to worsen over time, some advocate
prophylactic aortic valve repair at the time of LVAD implant in patients with more
than trivial aortic regurgitation (126).
Few patients (~3%) develop more than mild AR after LVAD (65). There are also
anecdotal reports of percutaneous transcatheter aortic valve closure in VAD
patients (127).

Arrhythmias
The frequency of ventricular tachycardia /fibrillation (VT/VF) has increased
significantly with the change from pulsatile to continuous flow VADs. VT/VF now
occurs in about one third of patients who have a continuous flow LVAD (128130). This problem is due in part to the new ability to adjust pump speed and
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instantaneously adjust preload. As a result, the LV chamber size can be reduced
until the septum touches the VAD drainage cannula. This causes a suction event
and triggers VT. Reducing the LVAD speed to expand the LV cavity may resolve
the issue. Other causes of VT/VF include a pre-existing post-MI myocardial scar,
as well as a new scar which can develop in a small percentage of patients at the
apical device cannulation site. VT/VF in this case can sometimes be treated
successfully by catheter ablation (131).
Because cardiac output in patients who have continuous flow LVADs is not
dependent on systole and diastole, ventricular arrhythmias are relatively well
tolerated. A continuous flow LVAD successfully provided hemodynamic support
to a patient in sustained ventricular fibrillation for over 12 hours (132). The effect
of automated implanted defibrillators on mortality in LVAD patients is
controversial. Some data show that the defibrillators still reduce mortality (129)
but other data show no impact (130, 133).
Although LVADs protect from hemodynamic compromise in arrhythmias, they
can initiate symptoms including right heart failure and recurrent syncope.
Persistent atrial fibrillation may be associated with increased mortality and HF
hospitalization, as well as with thromboembolism at higher levels of
anticoagulation (134). In persistent atrial flutter, radiofrequency ablation can
resolve symptoms (135).

Non-cardiac Surgery
As survival rates increase, patients with LVADs are developing additional health
problems that require treatment. This sometimes includes surgery. Non-cardiac
surgery in patients on continuous flow devices is a relatively new problem, and
there are very few studies addressing this issue.
In one cohort of 36 LVAD patients who underwent 63 non-cardiac surgeries, 30day mortality was 16% (136). Most of the surgeries were abdominal but
urological operations and craniotomies were also performed. None of the
patients who died were undergoing elective surgeries. All the deaths occurred in
patients who had to have emergent operations and half of these were
neurosurgeries for intracranial hemorrhage. Two-thirds of the surgeries did not
use Swan-Ganz catheters or arterial lines for monitoring. Mean blood pressure
was maintained above 70 mm Hg. LVAD parameters were monitored and
adjusted as required either by an LVAD coordinator or perfusionist experienced
with LVAD management (136).
In another series, 33 patients with LVADs underwent general anesthesia for 67
non-cardiac operations (91). Postoperative bleeding was the only complication
and this occurred in 12 patients. 3 patients died within 30 days of their operation
for reasons unrelated to the LVAD (91). A further study by Morgan et al. (137)
reports no peri-operative deaths, thromboembolic complications, or device
malfunction in 20 non-cardiac operations.
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Recommendations for patients on LVAD support undergoing a non-cardiac
operation include stopping warfarin and aspirin prior to the surgery and resuming
these drugs two weeks after the procedure. Vancomycin and cefazolin can be
administered before the surgery for antibiotic prophylaxis and continued for 24 to
48 hours postoperatively (136). Blood products can be used as needed, including
fresh frozen plasma and platelets.

LVAD Maintenance
Optimal outpatient management is the key to good outcomes in LVAD DT.
Although each LVAD center develops its own protocols, some principles have
become universal. The HF cardiologist and the VAD coordinator typically work
together and meet with the patient at each visit. It is helpful if the cardiothoracic
surgeon is available if needed.
Mean arterial pressure should be maintained in the 60 ~ 90 mm Hg range.
Conventional evidence-based medications for HF (angiotensin inhibitors and
receptor blockers, β-blockers, and aldosterone antagonists) should be continued
and increased if appropriate to achieve guideline targets.
Parameters of LVAD function including speed, power, and pulsatility index are
measured at each visit. Blood flow is estimated automatically from the power and
speed parameters. The only device parameter that can be manually adjusted is
the speed of the LVAD. For HMII devices, this is typically in the 8,600 ~ 9,800
revolutions per minute range. The pulsatility index is averaged over a defined
time interval and reflects the flow pulses created by LV contractions.
A recent paper by Topilsky et al. states that there are three goals for optimal
LVAD therapy: improved cardiac output, LV unloading and preserved pulsatility
(138). So-called “ramp” protocols are widely utilized to achieve these aims and
are normally performed under echocardiography guidance. The following
parameters are measured initially at baseline and then 3~5 minutes after each
change of LVAD speed: left ventricular dimension, frequency of the aortic valve
opening, and position of the interventricular septum. LVAD speed is usually
incremented in steps that are at least 400 revolutions per minute for HMII devices
and 60 revolutions per minute for Heartware systems. Once the protocol has
been completed, the cardiologist choses the single device setting (revolutions per
minute) that optimizes a middle position of the septum, intermittent valve
opening, and adequate unloading of the LV.
Setting the pump speed too low may result in an LV that appears dilated. A
recent publication suggests two novel parameters that may indicate insufficient
unloading of the LV. These are a rightward deflection of the atrial septum due to
high left atrial pressure and a mitral deceleration index (the ratio of deceleration
time to E-wave velocity) that is less than 2 ms / (cm s-1) (138).
Setting the pump speed too high can cause suction events where the ventricle
becomes decompressed and the septum shifts so far to the left that it gets
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sucked into the inflow cannula of the LVAD. This will reduce the power and
speed of the LVAD and can also initiate clinical episodes of VT.
Ramp protocols currently vary between institutions. Uriel et al. (102) have
recently proposed standardizing the approach and provide a detailed step by
step description of a protocol that can be used to optimize LVAD settings. They
also note that pump thrombosis is more likely if the LV end diastolic dimension is
relatively insensitive to the LVAD speed setting.

Cost of LVAD DT
LVAD DT using continuous flow devices is expensive but substantially cheaper
than support using pulsatile pumps ($193,812 versus $384,260 for initial
hospitalization, respectively, p < 0.001) (6). Although the cost of the actual
devices has not changed, the switch from pulsatile LVADs to continuous flow
devices is associated with a 50% reduction in the cost of implant hospitalization
over the last decade.
Taking into account hospital stays, re-hospitalizations, and Medicare payments
for professional services, the cost of LVAD therapy provides more qualityadjusted life years (QALY) (1.87 vs. 0.37), and life years (2.42 vs. 0.64), than
medical therapy. The downside is that the five-year costs of LVAD DT are much
higher ($360,407 vs. $62,856). The incremental cost-effectiveness ratio of the
continuous flow LVAD is estimated at $198,184 per QALY and $167,208 per life
year. This is a 75% reduction in incremental cost-effectiveness ratio from
$802,700 per QALY in 2004 (139). We conclude that although the cost of LVAD
therapy remains above the defined level of cost-effectiveness in the USA
($100,000 / incremental cost-effectiveness ratio) the trajectory is encouraging.
The most realistic way to reduce future costs is to prevent complications because
hospital readmissions are very expensive. Shifting the indications for LVAD
therapy towards “less sick” patients will also save costs because these
individuals will recover faster and develop fewer complications.

Conclusions
LVAD as a destination therapy prolongs life and improves its quality in thousands
of patients with end stage heart failure. In the future, smaller devices, freedom
from external driveline, better design and durability may further improve the
outcomes and make prosthetic pumps a more attractive option for patients with
less severe disease. Partial hemodynamic support, devices for short term right
ventricular support, and other innovations can potentially reduce complications of
current LVADs and result in even wider adoption of mechanical circulatory
support by both physicians’ community and general public.
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